Best of IGCS 2022 Annual Global Meeting-Plenary 01: Opening Ceremony and Oral Abstract Presentations

Video Transcription

Video Summary

In the SOLO3 trial, a post-hoc subgroup analysis was conducted to evaluate overall survival (OS) in patients with recurrent ovarian cancer treated with rucaparib, a PARP inhibitor. Comparing OS based on the number of prior lines of chemotherapy, the analysis found that rucaparib showed a potential survival benefit compared to chemotherapy in patients with two prior lines of chemotherapy. However, in patients with three or more prior lines of chemotherapy, chemotherapy had a numerical advantage over rucaparib. It is important to note that this analysis was not statistically significant due to its small sample size. The analysis also revealed that patients in the placebo arm, who received subsequent treatment, had a higher usage of PARP inhibitor therapy compared to the rucaparib arm. This suggests that the effectiveness of rucaparib may be influenced by the number of prior chemotherapy lines and subsequent treatments received. It is possible that rucaparib may lead to cross-resistance against subsequent platinum therapy, whereas non-cross-resistant drugs like Taxol or gemcitabine may not induce cross-resistance as much. The analysis also highlighted the presence of pre-existing BRCA reversion mutations, which might affect response to rucaparib and subsequent platinum therapy. However, these findings are only speculative and more research is necessary to fully understand the reasons behind the observed differences in OS based on prior lines of chemotherapy.

Keywords

SOLO3 trial

post-hoc analysis

overall survival

recurrent ovarian cancer

rucaparib

PARP inhibitor

prior lines of chemotherapy

survival benefit

chemotherapy

small sample size

placebo arm

PARP inhibitor therapy

cross-resistance

platinum therapy

BRCA reversion mutations